1 min listen
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
ratings:
Length:
21 minutes
Released:
Sep 23, 2022
Format:
Podcast episode
Description
In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches.
References
Kilagat K, Griffin MJ, Baik F, et al. Thyroid Care Collaborative: an electronic health record facilitating multidisciplinary management of thyroid cancer. Int J Endo Oncol 2018;5(1):IJE03
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the third objective.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosures:
Dr Lori Wirth
Advisory Board - Bayer Healthcare, Coherus, Eli Lilly, Eisai, Exelixis, PDS Biotechnology Corp
Consultant - Curie Therapeutics, Morphic Therapeutics
Dr. Thomas Giordano
No relevant disclosures to declare
References
Kilagat K, Griffin MJ, Baik F, et al. Thyroid Care Collaborative: an electronic health record facilitating multidisciplinary management of thyroid cancer. Int J Endo Oncol 2018;5(1):IJE03
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the third objective.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosures:
Dr Lori Wirth
Advisory Board - Bayer Healthcare, Coherus, Eli Lilly, Eisai, Exelixis, PDS Biotechnology Corp
Consultant - Curie Therapeutics, Morphic Therapeutics
Dr. Thomas Giordano
No relevant disclosures to declare
Released:
Sep 23, 2022
Format:
Podcast episode
Titles in the series (32)
Oncology Knowledge into Practice Trailer by Oncology Knowledge into Practice Podcast